Senseonics Haltings, Inc. (NYSE American: SENS), shares spiked 47.14% to $0.925 in the after-hours session Wednesday. The company has officially revealed financial and organizational modified products to design and commercialize long-term implantable continuous glucose monitoring systems (CGM).
Net sales are projected to amount to around $3.5 million in the fourth quarter of 2020 and rise from previous estimates by about $2.5 million.
The letter obtained from the FDA detailing agency personnel’s redislocation to fix COVID-19 public health product authorization (EUA) concerns marketing applications, including the Eversense 180-day product, which is being postponed by at least 60 days. Applications for COVID-19 public health products Senseonics believes that this is consistent with other medical technology firms’ findings.
Inclusion of Eversense Tier III CPT codes in the Practitioner Fee Schedule (PFS) 2021 Centers for Medicare & Medicaid Programs (CMS), facilitating global payment for the purchase of devices and procedural costs for healthcare providers across the U. S.
Net revenue is forecast to be within $12 and $15 million for the full year 2021, depending on the installed base, accelerating Ascensia’s market operations, and other factors.
The deal was concluded with Roche to promote the distribution transfer to Ascensia, as Roche sales end on 31 January 2021, comprising final orders, support activities for transition, and settlement of other issues.
By completing their second lien loans to common equity, Highbridge’s second-lien loan was extinguished, simplifying the United States’ financial structure.